Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 328

1.

Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease--results of the renal Hope-2 study.

Mann JF, Sheridan P, McQueen MJ, Held C, Arnold JM, Fodor G, Yusuf S, Lonn EM; HOPE-2 investigators..

Nephrol Dial Transplant. 2008 Feb;23(2):645-53. Epub 2007 Nov 14.

PMID:
18003666
2.

Homocysteine lowering with folic acid and B vitamins in vascular disease.

Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, McQueen MJ, Probstfield J, Fodor G, Held C, Genest J Jr; Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators..

N Engl J Med. 2006 Apr 13;354(15):1567-77. Epub 2006 Mar 12. Erratum in: N Engl J Med. 2006 Aug 17;355(7):746.

4.

Homocysteine lowering and cardiovascular events after acute myocardial infarction.

Bønaa KH, Njølstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, Wang H, Nordrehaug JE, Arnesen E, Rasmussen K; NORVIT Trial Investigators..

N Engl J Med. 2006 Apr 13;354(15):1578-88. Epub 2006 Mar 12.

5.

Rationale, design and baseline characteristics of a large, simple, randomized trial of combined folic acid and vitamins B6 and B12 in high-risk patients: the Heart Outcomes Prevention Evaluation (HOPE)-2 trial.

Lonn E, Held C, Arnold JM, Probstfield J, McQueen M, Micks M, Pogue J, Sheridan P, Bosch J, Genest J, Yusuf S; HOPE-2 Investigators..

Can J Cardiol. 2006 Jan;22(1):47-53.

6.

Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial.

Jamison RL, Hartigan P, Kaufman JS, Goldfarb DS, Warren SR, Guarino PD, Gaziano JM; Veterans Affairs Site Investigators..

JAMA. 2007 Sep 12;298(10):1163-70. Erratum in: JAMA. 2008 Jul 9;300(2):170.

PMID:
17848650
7.

Randomized controlled trial of homocysteine-lowering vitamin treatment in elderly patients with vascular disease.

Stott DJ, MacIntosh G, Lowe GD, Rumley A, McMahon AD, Langhorne P, Tait RC, O'Reilly DS, Spilg EG, MacDonald JB, MacFarlane PW, Westendorp RG.

Am J Clin Nutr. 2005 Dec;82(6):1320-6.

8.

Response of homocysteine, cystathionine, and methylmalonic acid to vitamin treatment in dialysis patients.

Obeid R, Kuhlmann MK, Köhler H, Herrmann W.

Clin Chem. 2005 Jan;51(1):196-201. Epub 2004 Nov 4.

9.
10.

Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial.

Albert CM, Cook NR, Gaziano JM, Zaharris E, MacFadyen J, Danielson E, Buring JE, Manson JE.

JAMA. 2008 May 7;299(17):2027-36. doi: 10.1001/jama.299.17.2027.

11.

Folic acid 5 or 15 mg/d similarly reduces plasma homocysteine in patients with moderate-advanced chronic renal failure.

Bernasconi AR, Liste A, Del Pino N, Rosa Diez GJ, Heguilén RM.

Nephrology (Carlton). 2006 Apr;11(2):137-41.

PMID:
16669976
12.

Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis: a meta-analysis.

Heinz J, Kropf S, Luley C, Dierkes J.

Am J Kidney Dis. 2009 Sep;54(3):478-89. doi: 10.1053/j.ajkd.2009.01.266. Epub 2009 Apr 8.

PMID:
19359080
13.

B vitamins and the risk of total mortality and cardiovascular disease in end-stage renal disease: results of a randomized controlled trial.

Heinz J, Kropf S, Domröse U, Westphal S, Borucki K, Luley C, Neumann KH, Dierkes J.

Circulation. 2010 Mar 30;121(12):1432-8. doi: 10.1161/CIRCULATIONAHA.109.904672. Epub 2010 Mar 15.

14.

Randomized, placebo-controlled trial of intramuscular vitamin B12 for the treatment of hyperhomocysteinaemia in dialysis patients.

Polkinghorne KR, Zoungas S, Branley P, Villanueva E, McNeil JJ, Atkins RC, McGrath BP, Kerr PG.

Intern Med J. 2003 Nov;33(11):489-94.

PMID:
14656250
15.

Homocysteine-lowering therapy does not affect inflammatory markers of atherosclerosis in patients with stable coronary artery disease.

Bleie Ø, Semb AG, Grundt H, Nordrehaug JE, Vollset SE, Ueland PM, Nilsen DW, Bakken AM, Refsum H, Nygård OK.

J Intern Med. 2007 Aug;262(2):244-53.

16.

Effect of homocysteine-lowering treatment with folic acid plus vitamin B on cerebrovascular atherosclerosis and white matter abnormalities as determined by MRA and MRI: a placebo-controlled, randomized trial.

Vermeulen EG, Stehouwer CD, Valk J, van der Knaap M, van den Berg M, Twisk JW, Prevoo W, Rauwerda JA.

Eur J Clin Invest. 2004 Apr;34(4):256-61.

PMID:
15086356
17.

Rationale and design of the Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT) trial.

Bostom AG, Carpenter MA, Kusek JW, Hunsicker LG, Pfeffer MA, Levey AS, Jacques PF, McKenney J; FAVORIT Investigators..

Am Heart J. 2006 Sep;152(3):448.e1-7.

PMID:
16923411
18.

Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial.

Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, Sides EG, Wang CH, Stampfer M.

JAMA. 2004 Feb 4;291(5):565-75.

PMID:
14762035
19.

Homocysteine lowering and cardiovascular disease risk: lost in translation.

Marcus J, Sarnak MJ, Menon V.

Can J Cardiol. 2007 Jul;23(9):707-10. Review.

20.

Supplemental Content

Support Center